Jump Therapeutics

Jump Therapeutics is reimagining precision oncology drug discovery by taking a closer look at transposable element dysregulation in cancer. These sequences, sometimes called “junk DNA” or genomic “dark matter,” may hold the key to more effective and universal treatments, broadly applicable across diverse cancer types. To date, Jump Therapeutics has achieved platform in vitro proof of concept and is currently seeking non-dilutive funding to advance in vivo studies.